We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+15.52%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$482M
AUM Growth
+$99.4M
(+26%)
Cap. Flow
+$75.7M
Cap. Flow
% of AUM
15.7%
Top 10 Holdings %
Top 10 Hldgs %
61.57%
Holding
55
New
16
Increased
8
Reduced
12
Closed
12
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
+$35.2M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$14.4M |
| 3 |
argenx
ARGX
|
+$12.7M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$12M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$11.1M |
Top Sells
| 1 |
Ascendis Pharma A/S
ASND
|
+$19.1M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$15.1M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$14.7M |
| 4 |
Travere Therapeutics
TVTX
|
+$11.3M |
| 5 |
AnaptysBio
ANAB
|
+$8.4M |
Sector Composition
| 1 | Healthcare | 72.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Sarepta Therapeutics
SRPT
$1.82B
| $44.1M | 9.14% |
+290,000
| New | +$35.2M |
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $43.9M | 9.1% |
+500,000
| New | +$42.6M |
|
3
PUT
Invesco QQQ Trust
QQQ
$466B
| $37.3M | 7.75% |
+200,000
| New | +$36.8M |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $35.4M | 7.34% |
375,000
+135,000
| +56% | +$11.1M |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $34.5M | 7.16% |
335,000
+185,000
| +123% | +$14.4M |
|
|
6
Ascendis Pharma A/S
ASND
$17.1B
| $25.9M | 5.37% |
225,000
-160,000
| -42% | -$19.1M |
|
7
Axsome Therapeutics
AXSM
$11.8B
| $21.9M | 4.54% |
850,000
+540,000
| +174% | +$10.8M |
|
8
Acadia Pharmaceuticals
ACAD
$4.38B
| $20M | 4.16% |
750,000
-150,000
| -17% | -$3.83M |
|
|
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
| $18.1M | 3.75% |
1,450,000
+150,000
| +12% | +$1.9M |
|
|
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $15.8M | 3.27% |
300,000
| – | – |
|
|
11
argenx
ARGX
$53.8B
| $14.2M | 2.94% |
+100,000
| New | +$12.7M |
|
|
IMMU
12
CALL
DELISTED
Immunomedics Inc
IMMU
| $11.1M | 2.3% |
+800,000
| New | +$12M |
|
13
Alnylam Pharmaceuticals
ALNY
$35.7B
| $10.9M | 2.26% |
150,000
| – | – |
|
|
14
BioCryst Pharmaceuticals
BCRX
$2.36B
| $9.47M | 1.97% |
2,500,000
+2,000,000
| +400% | +$12M |
|
|
RARX
15
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $9.02M | 1.87% |
300,000
| – | – |
|
16
Invesco CurrencyShares Swiss Franc Trust
FXF
$420M
| $8.75M | 1.82% |
92,200
+400
| +0.4% | +$37K |
|
|
IMMU
17
DELISTED
Immunomedics Inc
IMMU
| $8.32M | 1.73% |
600,000
-200,000
| -25% | -$3.01M |
|
|
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
| $7.16M | 1.49% |
1,000,000
+250,000
| +33% | +$2.83M |
|
19
Rocket Pharmaceuticals
RCKT
$376M
| $6.9M | 1.43% |
460,000
-140,000
| -23% | -$2.44M |
|
|
KALV
20
DELISTED
KalVista Pharmaceuticals
KALV
| $6.64M | 1.38% |
300,000
-100,000
| -25% | -$2.35M |
|
|
VRAY
21
DELISTED
ViewRay, Inc.
VRAY
| $6.61M | 1.37% |
750,000
| – | – |
|
22
Milestone Pharmaceuticals
MIST
$148M
| $6.52M | 1.35% |
+240,000
| New | +$4.95M |
|
23
PUT
Pfizer
PFE
$143B
| $6.5M | 1.35% |
+158,100
| New | +$6.28M |
|
|
MNTA
24
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $6.22M | 1.29% |
500,000
| – | – |
|
25
Zymeworks
ZYME
$1.78B
| $6.05M | 1.25% |
+275,000
| New | +$5.05M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q2 2019 Portfolio in Review
As of Q2 2019, Ghost Tree Capital held 55 positions worth $482M, up 26% from $383M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Ghost Tree Capital deployed $75.7M of net new capital in Q2 2019, opening 16 new positions and adding to 8 existing holdings. Its largest new stake was Sarepta Therapeutics: 290,000 shares worth $44.1M.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 84% a quarter earlier.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $19.1M trimmed.
- Ghost Tree Capital's largest Q2 2019 buy was Sarepta Therapeutics: 290,000 shares worth $44.1M.
- Ghost Tree Capital added most to Mirati Therapeutics, Inc. Common Stock in Q2 2019, an estimated $14.4M increase.
- Ghost Tree Capital's biggest Q2 2019 reduction was Ascendis Pharma A/S, cutting an estimated $19.1M.
- Ghost Tree Capital fully exited Vertex Pharmaceuticals in Q2 2019, selling an estimated $14.7M.
- Ghost Tree Capital's ten largest holdings make up 62% of its $482M portfolio in Q2 2019.
- Ghost Tree Capital opened 16 new positions and closed 12 in Q2 2019.
- Ghost Tree Capital's portfolio value rose 26% quarter-over-quarter to $482M.
Based on Ghost Tree Capital's 13F filing for Q2 2019, filed 14 Aug 2019.